Investor Presentation Q1 2018

Investor Presentation First three months of 2018 The GLP-1 segment accounts for around 5% of the total diabetes care market in Region Japan & Korea Japan & Korea GLP-1 market Slide 71 VictozaⓇ value market share in Japan & Korea GLP-1 value in bDKK VictozaⓇ exenatide dulaglutide Share of total other diabetes care market GLP-1 value VictozaⓇ market share exenatide dulaglutide other 1.6 3% 100% 1.4 CAGR value¹: 21.0% 80% 1.2 2% 1.0 60% 0.8 40% 53% 38% 0.6 1% 0.4 20% 0.2 0.0 0% 0% Feb 2013 Feb Feb 2018 2013 5% 4% Feb 2018 1 CAGR for 5-year period Source: IQVIA monthly MAT Feb, 2018 value figures (DKK) changing diabetes® Source: IQVIA monthly MAT Feb, 2018 value figures (DKK) novo nordisk

View entire presentation